Role of patatin-like phospholipase domain-containing 3 on lipid-induced hepatic steatosis and insulin resistance in rats

Hepatology

Volumn 57, Issue 5, 2013, Pages 1763-1772

  Kumashiro, Naoki ^a   Yoshimura, Toru ^a   Cantley, Jennifer L ^a   Majumdar, Sachin K ^a   Guebre Egziabher, Fitsum ^a   Kursawe, Romy ^a   Vatner, Daniel F ^a   Fat, Ioana ^a   Kahn, Mario ^a   Erion, Derek M ^a   Zhang, Xian Man ^a   Zhang, Dongyan ^a   Manchem, Vara Prasad ^b   Bhanot, Sanjay ^b   Gerhard, Glenn S ^c   Petersen, Kitt F ^a   Cline, Gary W ^a   Samuel, Varman T ^a,d   Shulman, Gerald I ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ISIS PHARMACEUTICALS   (United States)

^c WEIS CENTER FOR RESEARCH   (United States)

^d VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ACYLGLYCEROPHOSPHATE ACYLTRANSFERASE; ACYL COENZYME A; ACYL COENZYME A: 1 ACYLGLYCEROL SN 3 PHOSPHATE ACYLTRANSFERASE; ANTISENSE OLIGONUCLEOTIDE; DIACYLGLYCEROL; FATTY ACID; GLUCOSE; INSULIN; LIPID; LONG CHAIN FATTY ACYL COENZYME A; LYSOPHOSPHATIDIC ACID; MESSENGER RNA; PALMITIC ACID C 13; PATATIN LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3; PHOSPHATIDIC ACID; PHOSPHOLIPASE; PROTEIN KINASE C EPSILON; RADIOISOTOPE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ESTERIFICATION; FATTY LIVER; GENE EXPRESSION; GLUCONEOGENESIS; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID ANALYSIS; LIPID DIET; LIPOGENESIS; LIVER; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RAT; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; BIOPSY; DIET, HIGH-FAT; DIGLYCERIDES; DISEASE MODELS, ANIMAL; FATTY ACIDS; FATTY LIVER; HUMANS; INSULIN RESISTANCE; LIPIDS; LIVER; MALE; MEMBRANE PROTEINS; OLIGONUCLEOTIDES, ANTISENSE; PHOSPHOLIPASES A2; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; TRIGLYCERIDES;

EID: 84876718085     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26170     Document Type: Article

References (46)

1. Samuel VT, Shulman GI. Mechanisms for insulin resistance: common threads and missing links. Cell 2012; 148: 852-871.
2. Cheung O, Sanyal AJ. Recent advances in nonalcoholic fatty liver disease. Curr Opin Gastroenterol 2010; 26: 202-208.
3. Kantartzis K, Peter A, Machicao F, Machann J, Wagner S, Konigsrainer I, et al. Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes 2009; 58: 2616-2623.
4. Chang CY. Understanding the relationship between PNPLA3, NAFLD and insulin resistance: do ethnic differences bring more questions or more answers? Liver Int 2011; 31: 1246-1249.
5. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40: 1461-1465.
6. Rotman Y, Koh C, Zmuda JM, Kleiner DE, Liang TJ. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. HEPATOLOGY 2010; 52: 894-903.
7. Sookoian S, Castano GO, Burgueno AL, Gianotti TF, Rosselli MS, Pirola CJ. A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity. J Lipid Res 2009; 50: 2111-2116.
8. Wang CW, Lin HY, Shin SJ, Yu ML, Lin ZY, Dai CY, et al. The PNPLA3 I148M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic population. Liver Int 2011; 31: 1326-1331.
9. Petersen KF, Dufour S, Hariri A, Nelson-Williams C, Foo JN, Zhang XM, et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med 2010; 362: 1082-1089.
10. Kumari M, Schoiswohl G, Chitraju C, Paar M, Cornaciu I, Rangrez AY, et al. Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase. Cell Metab 2012; 15: 691-702.
11. He S, McPhaul C, Li JZ, Garuti R, Kinch L, Grishin NV, et al. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem 2010; 285: 6706-6715.
12. Huang Y, Cohen JC, Hobbs HH. Expression and characterization of a PNPLA3 protein isoform (I148M) associated with nonalcoholic fatty liver disease. J Biol Chem 2011; 286: 37085-37093.
13. Perttila J, Huaman-Samanez C, Caron S, Tanhuanpaa K, Staels B, Yki-Jarvinen H, et al. Pnpla3 is regulated by glucose in human hepatocytes and its I148m mutant slows down triglyceride hydrolysis. Am J Physiol Endocrinol Metab 2012; 302: E1063-1069.
14. Jenkins CM, Mancuso DJ, Yan W, Sims HF, Gibson B, Gross RW. Identification, cloning, expression, and purification of three novel human calcium-independent phospholipase A2 family members possessing triacylglycerol lipase and acylglycerol transacylase activities. J Biol Chem 2004; 279: 48968-48975.
15. Qiao A, Liang J, Ke Y, Li C, Cui Y, Shen L, et al. Mouse patatin-like phospholipase domain-containing 3 influences systemic lipid and glucose homeostasis. HEPATOLOGY 2011; 54: 509-521.
16. Basantani MK, Sitnick MT, Cai L, Brenner DS, Gardner NP, Li JZ, et al. Pnpla3/Adiponutrin deficiency in mice does not contribute to fatty liver disease or metabolic syndrome. J Lipid Res 2011; 52: 318-329.
17. Chen W, Chang B, Li L, Chan L. Patatin-like phospholipase domain-containing 3/adiponutrin deficiency in mice is not associated with fatty liver disease. HEPATOLOGY 2010; 52: 1134-1142.
18. Palmer CN, Maglio C, Pirazzi C, Burza MA, Adiels M, Burch L, et al. Paradoxical lower serum triglyceride levels and higher type 2 diabetes mellitus susceptibility in obese individuals with the PNPLA3 148M variant. PLoS One 2012; 7: e39362.
19. Storlien LH, Jenkins AB, Chisholm DJ, Pascoe WS, Khouri S, Kraegen EW. Influence of dietary fat composition on development of insulin resistance in rats. Relationship to muscle triglyceride and omega-3 fatty acids in muscle phospholipid. Diabetes 1991; 40: 280-289.
20. Choi CS, Befroy DE, Codella R, Kim S, Reznick RM, Hwang YJ, et al. Paradoxical effects of increased expression of PGC-1alpha on muscle mitochondrial function and insulin-stimulated muscle glucose metabolism. Proc Natl Acad Sci U S A 2008; 105: 19926-19931.
21. Yu C, Chen Y, Cline GW, Zhang D, Zong H, Wang Y, et al. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem 2002; 277: 50230-50236.
22. Neschen S, Moore I, Regittnig W, Yu CL, Wang Y, Pypaert M, et al. Contrasting effects of fish oil and safflower oil on hepatic peroxisomal and tissue lipid content. Am J Physiol Endocrinol Metab 2002; 282: E395-401.
23. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959; 37: 911-917.
24. Bogan JS, McKee AE, Lodish HF. Insulin-responsive compartments containing GLUT4 in 3T3-L1 and CHO cells: regulation by amino acid concentrations. Mol Cell Biol 2001; 21: 4785-4806.
25. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29: e45.
26. Kumashiro N, Erion DM, Zhang D, Kahn M, Beddow SA, Chu X, et al. Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc Natl Acad Sci U S A 2011; 108: 16381-16385.
27. Griffin ME, Marcucci MJ, Cline GW, Bell K, Barucci N, Lee D, et al. Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. Diabetes 1999; 48: 1270-1274.
28. Samuel VT, Liu ZX, Wang A, Beddow SA, Geisler JG, Kahn M, et al. Inhibition of protein kinase Cepsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease. J Clin Invest 2007; 117: 739-745.
29. Nagai Y, Yonemitsu S, Erion DM, Iwasaki T, Stark R, Weismann D, et al. The role of peroxisome proliferator-activated receptor gamma coactivator-1 beta in the pathogenesis of fructose-induced insulin resistance. Cell Metab 2009; 9: 252-264.
30. Lee WN, Bassilian S, Ajie HO, Schoeller DA, Edmond J, Bergner EA, et al. In vivo measurement of fatty acids and cholesterol synthesis using D2O and mass isotopomer analysis. Am J Physiol 1994; 266: E699-708.
31. Weiss R, Taksali SE, Dufour S, Yeckel CW, Papademetris X, Cline G, et al. The "obese insulin-sensitive" adolescent: importance of adiponectin and lipid partitioning. J Clin Endocrinol Metab 2005; 90: 3731-3737.
32. Neschen S, Morino K, Hammond LE, Zhang D, Liu ZX, Romanelli AJ, et al. Prevention of hepatic steatosis and hepatic insulin resistance in mitochondrial acyl-CoA:glycerol-sn-3-phosphate acyltransferase 1 knockout mice. Cell Metab 2005; 2: 55-65.
33. Chu X, Erdman R, Susek M, Gerst H, Derr K, Al-Agha M, et al. Association of morbid obesity with FTO and INSIG2 allelic variants. Arch Surg 2008; 143: 235-240; discussion 241.
34. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. HEPATOLOGY 2005; 41: 1313-1321.
35. Sazani P, Gemignani F, Kang SH, Maier MA, Manoharan M, Persmark M, et al. Systemically delivered antisense oligomers upregulate gene expression in mouse tissues. Nat Biotechnol 2002; 20: 1228-1233.
36. Hoekstra M, Li Z, Kruijt JK, Van Eck M, Van Berkel TJ, Kuiper J. The expression level of non-alcoholic fatty liver disease-related gene PNPLA3 in hepatocytes is highly influenced by hepatic lipid status. J Hepatol 2010; 52: 244-251.
37. Huang Y, He S, Li JZ, Seo YK, Osborne TF, Cohen JC, et al. A feed-forward loop amplifies nutritional regulation of PNPLA3. Proc Natl Acad Sci U S A 2010; 107: 7892-7897.
38. Kershaw EE, Hamm JK, Verhagen LA, Peroni O, Katic M, Flier JS. Adipose triglyceride lipase: function, regulation by insulin, and comparison with adiponutrin. Diabetes 2006; 55: 148-157.
39. Caimari A, Oliver P, Palou A. Regulation of adiponutrin expression by feeding conditions in rats is altered in the obese state. Obesity 2007; 15: 591-599.
40. Santoro N, Kursawe R, D'Adamo E, Dykas DJ, Zhang CK, Bale AE, et al. A common variant in the patatin-like phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents. HEPATOLOGY 2010; 52: 1281-1290.
41. Jornayvaz FR, Shulman GI. Diacylglycerol activation of protein kinase cepsilon and hepatic insulin resistance. Cell Metab 2012; 15: 574-584.
42. Rae-Whitcombe SM, Kennedy D, Voyles M, Thompson MP. Regulation of the promoter region of the human adiponutrin/PNPLA3 gene by glucose and insulin. Biochem Biophys Res Commun 2010; 402: 767-772.
43. Ferre P, Foufelle F. Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c. Diabetes Obes Metab 2010; 12( Suppl 2): 83-92.
44. Dentin R, Girard J, Postic C. Carbohydrate responsive element binding protein (ChREBP) and sterol regulatory element binding protein-1c (SREBP-1c): two key regulators of glucose metabolism and lipid synthesis in liver. Biochimie 2005; 87: 81-86.
45. Pirazzi C, Adiels M, Burza MA, Mancina RM, Levin M, Stahlman M, et al. Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro. J Hepatol 2012; 57: 1276-1282.
46. Li JZ, Huang Y, Karaman R, Ivanova PT, Brown HA, Roddy T, et al. Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis. J Clin Invest 2012 [Epub ahead of print].